// App-Quantinova.ai

2349 : Evaluation of the combination of the prodrug-mediated gene therapy vector AdV-tk and immune checkpoint inhibitor for glioblastoma treatment in a syngeneic mouse model

Researchers

Presenter

  • Maria Carmela Speranza

Principal Investigators

  • Kazue Kasai

  • Johanna Kaufmann

  • Estuardo Aguilar-Cordova

  • Brian W. Guzik

  • E. Antonio Chiocca

  • Sean Lawler

Medical Centers

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA.

  • Advantagene Inc, Auburndale, MA

Locations

  • United States

Companies

  • Advantagene, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Brain cancer

  • Melanoma

  • Solid malignancies

  • Gliomas

Biomarkers

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

Drug/Treatment

  • Ganciclovir

  • Adv-tk

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved